Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19

Figen Güzelgül; Marwa Abdelmageed; Handan İnönü Köseoğlu; Esma Akpınar Aslan

doi:10.54187/jnrs.1835676

Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19

Abstract

Insomnia is a prevalent symptom affecting 5.4% to 64% of individuals who have recovered from coronavirus disease 2019 (COVID-19). In this study, we aimed to elucidate the role of copeptin and melatonin in the pathogenesis of post-COVID-19 and insomnia in COVID-19 survivors. Thirty COVID-19-recovered patients and fifteen healthy controls were included in the study. Patients were categorized into two groups: Individuals with post-COVID insomnia having an insomnia severity index (ISI) score above 15 (n=10) and those without (n=20). Insomnia patients received either trazodone 50 mg or mirtazapine 15 mg as a sleep disturbance treatment once a day for three months. Serum copeptin and melatonin were evaluated. Melatonin and copeptin levels demonstrated a statistical significance between the study groups (p<0.008 and p=0.039, respectively). Furthermore, the three cases who completed three months of treatment reported sleep improvement associated with a reduction in copeptin levels and an elevation in melatonin levels. To our knowledge, this study is the first to investigate copeptin levels in non-hospitalized recovered COVID-19 subjects with insomnia. Our data suggest a potential correlation between serum copeptin and insomnia among COVID-19-recovered patients. Further studies with larger cohorts could investigate the potential of copeptin as a predictive biomarker for post-COVID insomnia.

Keywords

Copeptin, COVID-19, insomnia, melatonin

Supporting Institution

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Project Number

There is no project number

Ethical Statement

The study received approval from the Ethics Committee of the Faculty of Medicine, TTokat Gaziosmanpaşa University, Tokat City, Türkiye (approval number: 21-KAEK-252, Date: 22.12.2021). Informed written consent was obtained from all participants, in full compliance with the Declaration of Helsinki.

Thanks

The authors would like to express their gratitude to all participants in this study.

References

World Health Organization. WHO COVID-19 dashboard – Cases (2025) Accessed 10 July 2025.
M. Garg, M. Maralakunte, S. Garg, S. Dhooria, I. Sehgal, A. S. Bhalla, R. Vijayvergiya, S. Grover, V. Bhatia, …, M. S. Sandhu, The conundrum of ‘Long-COVID-19ʹ, a narrative review, International Journal of General Medicine 14 (2021) 2491–2506.
J. B. Soriano, S. Murthy, J. C. Marshall, P. Relan, J. V. Diaz, A clinical case definition of post-COVID-19 condition by a Delphi consensus, The Lancet Infectious Diseases 22 (4) (2022) e102–e107.
D. Gonçalves, J. P. Costa, S. Silva, M. Tavares, H. Barros, P. Meireles, The association between probable POST‐COVID ‐19 condition and sleep‐related parameters: A longitudinal study of non‐hospitalised patients, Journal of Sleep Research 33 (6) (2024) e14215.
O. V. Kotova, V. E. Medvedev, M. G. Poluektov, A. A. Belyaev, E. S. Akarachkova, Sleep disorders in Post-COVID syndrome: A psychiatric or neurological problem?, Neuroscience and Behavioral Physiology 53 (1) (2023) 16–20.
V. Chippa, A. Aleem, F. Anjum. Postacute coronavirus (COVID-19) syndrome, StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2025.
N. L. Rauwerda, T. A. Kuut, A. M. J. Braamse, I. Csorba, P. Nieuwkerk, A. Van Straten, H. Knoop, Insomnia and sleep characteristics in post COVID-19 fatigue: A cross-sectional case-controlled study, Journal of Psychosomatic Research 177 (2024) 111522.
R. Tedjasukmana, A. Budikayanti, W. R. Islamiyah, A. M. A. L. Witjaksono, M. Hakim, Sleep disturbance in post COVID-19 conditions: Prevalence and quality of life, Frontiers in Neurology 13 (2023) 1095606.
H. M. Al-Kuraishy, A. I. Al-Gareeb, S. Qusti, E. M. Alshammari, F. O. Atanu, G. E.- S. Batiha, Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective, Biomedicine and Pharmacotherapy 143 (2021) 112193.
E. Solomonova, Y. E. A. Lee, S. Robins, L. King, N. Feeley, I. Gold, B. Hayton, E. Libman, C. Nagy, …, P. Zelkowitz, Sleep quality is associated with vasopressin methylation in pregnant and postpartum women with a history of psychosocial stress, Psychoneuroendocrinology 107 (2019) 160–168.

M. Abdelmageed, F. Güzelgül, Copeptin: Up-to-date diagnostic and prognostic role highlight, Analytical Biochemistry 673 (2023) 115181.
R. J. Dressle, B. Feige, K. Spiegelhalder, C. Schmucker, F. Benz, N. C. Mey, D. Riemann, HPA axis activity in patients with chronic insomnia: A systematic review and meta-analysis of case–control studies, Sleep Medicine Reviews 62 (2022) 101588.
D. A. Schmid, A. Wichniak, M. Uhr, M. Ising, H. Brunner, K. Held, J. C. Weikel, A. Sonntag, A. Steiger, Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine, Neuropsychopharmacology 31 (4) (2006) 832–844.
K. Y. Jaffer, T. Chang, B. Vanle, J. Dang, A. J. Steiner, N. Loera, M. Abdelmesseh, I. Danovitch, W. W. Ishak, Trazodone for insomnia: A systematic review, Innovations in Clinical Neuroscience 14 (7–8) (2017) 24–34.
C. M. Morin, G. Belleville, L. Bélanger, H. Ivers, The insomnia severity index: Psychometric indicators to detect insomnia cases and evaluate treatment response, Sleep 34 (5) (2011) 601–608.
H. T. X. Hoang, W. F. Yeung, Q. T. M. Truong, C. T. Le, A. T. M. Bui, Q. V. Bui, Q. T. L. Le, L. H. Quach, Sleep quality among non-hospitalized COVID-19 survivors: A national cross-sectional study, Frontiers in Public Health 11 (2024) 1281012.
X. X. Zhang, S. Y. Sun, Z. J. Ma, Z. Y. Li, Y. S. Zhou, Y. Yang, J. X. Rao, P. Zhang, X. Y. Kong, …, G. H. Chen, Changed nocturnal levels of stress-related hormones couple with sleep-wake states in the patients with chronic insomnia disorder: A clinical pilot study, Sleep Medicine 117 (2024) 177–183.
P. L. Nonglait, S. V. Madhu, N. Raizada, A. Aggarwal, R. Ahmed, M. Aslam, High level of psychological stress in COVID-19 recovered individuals: Role of copeptin as a potential biomarker, Frontiers in Psychology 14 (2023) 1253396.
J. T. Chen, P. Zhang, X. Y. Kong, Y. J. Ge, X. Y. Li, S. Yang, S. He, G. H. Chen, Changed serum levels of CD62E+, angiotensin II and copeptin in patients with chronic insomnia disorder: A link between insomnia and stroke?, Sleep Medicine 91 (2022) 96–104.
S. Schreiber, C. G. Pick, Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?, Medical Hypotheses 136 (2020) 109501.
S. M. Stahl, Mechanism of action of trazodone: A multifunctional drug, CNS Spectrums 14 (10) (2009) 536–546.
C. L. DeVane, D. R. Grothe, S. L. Smith, Pharmacology of antidepressants: Focus on nefazodone, Journal of Clinical Psychiatry 63 (1) (2002) 10–17.
A. Agorastos, A. Sommer, A. Heinig, K. Wiedemann, C. Demiralay, Vasopressin surrogate marker copeptin as a potential novel endocrine biomarker for antidepressant treatment response in major depression: A pilot study, Frontiers in Psychiatry 11 (2020) 453.
M. Adamsson, T. Laike, T. Morita, Annual variation in daily light exposure and circadian change of melatonin and cortisol concentrations at a northern latitude with large seasonal differences in photoperiod length, Journal of Physiological Anthropology 36 (1) (2017) 6.
B. Rzepka-Migut, J. Paprocka, Melatonin-measurement methods and the factors modifying the results. A systematic review of the literature, International Journal of Environmental Research and Public Health 17 (6) (2020) 1916.

Details

Primary Language

English

Subjects

Proteomics and Intermolecular Interactions, Biochemistry and Cell Biology (Other)

Journal Section

Research Article

Authors

Figen Güzelgül ^*
0000-0002-2796-9511
Türkiye

Marwa Abdelmageed
0000-0003-0695-326X
Türkiye

Handan İnönü Köseoğlu
0000-0002-7901-3466
Türkiye

Esma Akpınar Aslan
0000-0003-4714-6894
Türkiye

Publication Date

April 30, 2026

Submission Date

December 4, 2025

Acceptance Date

March 2, 2026

Published in Issue

Year 2026 Volume: 15 Number: 1

DOI

https://doi.org/10.54187/jnrs.1835676

IZ

https://izlik.org/JA62AK97SE

APA

Güzelgül, F., Abdelmageed, M., İnönü Köseoğlu, H., & Akpınar Aslan, E. (2026). Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19. Journal of New Results in Science, 15(1), 84-94. https://doi.org/10.54187/jnrs.1835676

AMA

1.Güzelgül F, Abdelmageed M, İnönü Köseoğlu H, Akpınar Aslan E. Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19. JNRS. 2026;15(1):84-94. doi:10.54187/jnrs.1835676

Chicago

Güzelgül, Figen, Marwa Abdelmageed, Handan İnönü Köseoğlu, and Esma Akpınar Aslan. 2026. “Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19”. Journal of New Results in Science 15 (1): 84-94. https://doi.org/10.54187/jnrs.1835676.

EndNote

Güzelgül F, Abdelmageed M, İnönü Köseoğlu H, Akpınar Aslan E (April 1, 2026) Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19. Journal of New Results in Science 15 1 84–94.

IEEE

[1]F. Güzelgül, M. Abdelmageed, H. İnönü Köseoğlu, and E. Akpınar Aslan, “Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19”, JNRS, vol. 15, no. 1, pp. 84–94, Apr. 2026, doi: 10.54187/jnrs.1835676.

ISNAD

Güzelgül, Figen - Abdelmageed, Marwa - İnönü Köseoğlu, Handan - Akpınar Aslan, Esma. “Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19”. Journal of New Results in Science 15/1 (April 1, 2026): 84-94. https://doi.org/10.54187/jnrs.1835676.

JAMA

1.Güzelgül F, Abdelmageed M, İnönü Köseoğlu H, Akpınar Aslan E. Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19. JNRS. 2026;15:84–94.

MLA

Güzelgül, Figen, et al. “Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19”. Journal of New Results in Science, vol. 15, no. 1, Apr. 2026, pp. 84-94, doi:10.54187/jnrs.1835676.

Vancouver

1.Figen Güzelgül, Marwa Abdelmageed, Handan İnönü Köseoğlu, Esma Akpınar Aslan. Stress Markers and Post-COVID Insomnia: Investigating Copeptin and Melatonin Levels in Post-COVID-19. JNRS. 2026 Apr. 1;15(1):84-9. doi:10.54187/jnrs.1835676